Age-related differences in reporting of drug-associated liver injury: data-mining of WHO Safety Report Database.

[1]  O. Caster,et al.  Methylprednisolone-induced hepatotoxicity: experiences from global adverse drug reaction surveillance , 2014, European Journal of Clinical Pharmacology.

[2]  Cynthia A Afshari,et al.  A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. , 2013, Toxicological sciences : an official journal of the Society of Toxicology.

[3]  A. Tropsha,et al.  An updated review on drug-induced cholestasis: mechanisms and investigation of physicochemical properties and pharmacokinetic parameters. , 2013, Journal of pharmaceutical sciences.

[4]  Weida Tong,et al.  High lipophilicity and high daily dose of oral medications are associated with significant risk for drug‐induced liver injury , 2013, Hepatology.

[5]  G. Ubeaud‐Séquier,et al.  Implication of hepatic transporters (MDR1 and MRP2) in inflammation‐associated idiosyncratic drug‐induced hepatotoxicity investigated by microvolume cytometry , 2013, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[6]  Marija Petronijevic,et al.  Associations of Gender and Age with the Reporting of Drug‐Induced Hepatic Failure: Data from the VigiBase™ , 2013, Journal of clinical pharmacology.

[7]  G. Aithal,et al.  Hepatotoxicity Related to Anti-tuberculosis Drugs: Mechanisms and Management. , 2013, Journal of clinical and experimental hepatology.

[8]  J. Ambroso,et al.  Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. , 2012, Chemical research in toxicology.

[9]  S. Karras,et al.  Pathogenesis of propylthiouracil-related hepatotoxicity in children: present concepts , 2012, Journal of pediatric endocrinology & metabolism : JPEM.

[10]  Yan Li,et al.  In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs. , 2012, Chemical research in toxicology.

[11]  Yi-Shin Huang.  Recent global endeavors in the detection and prevention of drug-induced liver injury. , 2012, Journal of the Formosan Medical Association = Taiwan yi zhi.

[12]  D. Pessayre,et al.  Central role of mitochondria in drug-induced liver injury , 2012, Drug metabolism reviews.

[13]  C. Day,et al.  Genetic association studies in drug-induced liver injury , 2012, Drug metabolism reviews.

[14]  J. G. Kenna,et al.  In Vitro Inhibition of the Bile Salt Export Pump Correlates with Risk of Cholestatic Drug-Induced Liver Injury in Humans , 2012, Drug Metabolism and Disposition.

[15]  J. Esplugues,et al.  Mitochondrial interference by anti-HIV drugs: mechanisms beyond Pol-γ inhibition. , 2011, Trends in pharmacological sciences.

[16]  Bonaventura Clotet,et al.  Drug uptake transporters in antiretroviral therapy. , 2011, Pharmacology & therapeutics.

[17]  D. L. Schmucker,et al.  Liver Regeneration and Aging: A Current Perspective , 2011, Current gerontology and geriatrics research.

[18]  Jiezhun Gu,et al.  Characteristics of Idiosyncratic Drug-induced Liver Injury in Children: Results From the DILIN Prospective Study , 2011, Journal of pediatric gastroenterology and nutrition.

[19]  P. Hohensinner,et al.  Telomere dysfunction, autoimmunity and aging. , 2011, Aging and disease.

[20]  Munir Pirmohamed,et al.  Drug Induced Hypersensitivity and the HLA Complex , 2010, Pharmaceuticals.

[21]  M. Schuemie,et al.  Drug-induced hepatic injury in children: a case/non-case study of suspected adverse drug reactions in VigiBase. , 2010, British journal of clinical pharmacology.

[22]  Li-Hsin Chen,et al.  microRNA and aging: A novel modulator in regulating the aging network , 2010, Ageing Research Reviews.

[23]  A. Jetter,et al.  Pharmacogenetics of drug‐induced liver injury , 2010, Hepatology.

[24]  R. Yung,et al.  The Role of Epigenetics in Aging and Autoimmunity , 2010, Clinical reviews in allergy & immunology.

[25]  Y. Will,et al.  High-Content Screening for Compounds That Affect mtDNA-Encoded Protein Levels in Eukaryotic Cells , 2010, Journal of biomolecular screening.

[26]  S. Rivkees,et al.  Dissimilar hepatotoxicity profiles of propylthiouracil and methimazole in children. , 2010, The Journal of clinical endocrinology and metabolism.

[27]  William M. Lee,et al.  Drugs Associated with Hepatotoxicity and their Reporting Frequency of Liver Adverse Events in VigiBase™ , 2010, Drug safety.

[28]  Katalin Jemnitz,et al.  Biliary efflux transporters involved in the clearance of rosuvastatin in sandwich culture of primary rat hepatocytes. , 2010, Toxicology in vitro : an international journal published in association with BIBRA.

[29]  E. Bjornsson,et al.  Oral medications with significant hepatic metabolism at higher risk for hepatic adverse events , 2010, Hepatology.

[30]  K. Brouwer,et al.  Use of cassette dosing in sandwich-cultured rat and human hepatocytes to identify drugs that inhibit bile acid transport. , 2010, Toxicology in vitro : an international journal published in association with BIBRA.

[31]  William M. Lee,et al.  Outcome of acute liver failure in the elderly , 2009, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[32]  C. Day,et al.  Genetic association studies in drug-induced liver injury. , 2009, Seminars in liver disease.

[33]  M. Niemi,et al.  Impact of OATP transporters on pharmacokinetics , 2009, British journal of pharmacology.

[34]  L. Magder,et al.  Outcome of liver transplantation for drug‐induced acute liver failure in the United States: Analysis of the united network for organ sharing database , 2009, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[35]  R. Andrade,et al.  Phenotypic characterization of idiosyncratic drug‐induced liver injury: The influence of age and sex , 2009, Hepatology.

[36]  V. Ramesh,et al.  Reversible valproate hepatotoxicity due to mutations in mitochondrial DNA polymerase &ggr; (POLG1) , 2009, BMJ Case Reports.

[37]  Ulrich Klotz,et al.  Pharmacokinetics and drug metabolism in the elderly , 2009, Drug metabolism reviews.

[38]  N. Hadžić,et al.  Drug-related hepatotoxicity and acute liver failure. , 2008, Journal of pediatric gastroenterology and nutrition.

[39]  M. Lindquist.  VigiBase, the WHO Global ICSR Database System: Basic Facts , 2008 .

[40]  G. López-Lluch,et al.  Mitochondrial biogenesis and healthy aging , 2008, Experimental Gerontology.

[41]  Chandan Saha,et al.  Relationship between daily dose of oral medications and idiosyncratic drug‐induced liver injury: Search for signals , 2008, Hepatology.

[42]  J. Wyman,et al.  Use of complementary and alternative therapies in community-dwelling older adults. , 2007, Journal of alternative and complementary medicine.

[43]  T. J. Moore,et al.  Serious adverse drug events reported to the Food and Drug Administration, 1998-2005. , 2007, Archives of internal medicine.

[44]  Yvonne Will,et al.  Strategies to reduce late-stage drug attrition due to mitochondrial toxicity , 2007, Expert review of molecular diagnostics.

[45]  M. Hurwitz,et al.  Roxithromycin induced hypersensitivity pneumonitis. , 2006, Pathology.

[46]  P. Meier,et al.  Hepatobiliary transporters and drug‐induced cholestasis , 2006, Hepatology.

[47]  A. Santra,et al.  Mitochondrial oxidative stress and permeability transition in isoniazid and rifampicin induced liver injury in mice. , 2006, Journal of hepatology.

[48]  J. Schwartz,et al.  Erythromycin breath test results in elderly, very elderly, and frail elderly persons , 2006, Clinical pharmacology and therapeutics.

[49]  D. Menzies,et al.  Adverse reactions to first-line antituberculosis drugs , 2006, Expert opinion on drug safety.

[50]  Robert H. Squires,et al.  Acute Liver Failure in Children , 2008, Seminars in liver disease.

[51]  W. DuMouchel,et al.  Comparative Performance of Two Quantitative Safety Signalling Methods , 2006, Drug safety.

[52]  K. Brouwer,et al.  MULTIPLE MECHANISMS ARE INVOLVED IN THE BILIARY EXCRETION OF ACETAMINOPHEN SULFATE IN THE RAT: ROLE OF MRP2 AND BCRP1 , 2005, Drug Metabolism and Disposition.

[53]  K. Turnheim.  Pharmacokinetic dosage guidelines for elderly subjects , 2005, Expert opinion on drug metabolism & toxicology.

[54]  Joseph M. Tonning,et al.  Perspectives on the Use of Data Mining in Pharmacovigilance , 2005, Drug safety.

[55]  F. D. de Abajo,et al.  Acute and clinically relevant drug-induced liver injury: a population based case-control study. , 2004, British journal of clinical pharmacology.

[56]  G. Farrell,et al.  Toxicity of low dose azathioprine and 6-mercaptopurine in rat hepatocytes. Roles of xanthine oxidase and mitochondrial injury. , 2004, Journal of hepatology.

[57]  J. Nicolas,et al.  Skin delayed‐type hypersensitivity to josamycin , 2003, Allergy.

[58]  Susan M Abdel-Rahman,et al.  Developmental pharmacology--drug disposition, action, and therapy in infants and children. , 2003, The New England journal of medicine.

[59]  D. Bates,et al.  Incidence and preventability of adverse drug events among older persons in the ambulatory setting. , 2003, JAMA.

[60]  William M. Lee,et al.  Results of a Prospective Study of Acute Liver Failure at 17 Tertiary Care Centers in the United States , 2002, Annals of Internal Medicine.

[61]  P. Hillon,et al.  Incidence of drug‐induced hepatic injuries: A French population‐based study , 2002, Hepatology.

[62]  D. Keppler,et al.  Inhibition of transport across the hepatocyte canalicular membrane by the antibiotic fusidate. , 2002, Biochemical pharmacology.

[63]  U. Boelsterli.  Mechanisms of NSAID-Induced Hepatotoxicityon Nimesulide , 2002 .

[64]  A. Bernareggi.  Clinical Pharmacokinetics of Nimesulide , 1998, Clinical pharmacokinetics.

[65]  V. Desmet,et al.  Nimesulide-induced acute hepatitis: evidence from six cases. , 1998, Journal of hepatology.

[66]  J. Rosh,et al.  Four cases of severe hepatotoxicity associated with pemoline: possible autoimmune pathogenesis. , 1998, Pediatrics.

[67]  E. Roberts,et al.  Pemoline hepatotoxicity in children. , 1998, The Journal of pediatrics.

[68]  W. Kuhnz,et al.  PHARMACOKINETICS AND DISPOSITION , 1997 .

[69]  C. Hunt,et al.  Effect of age and gender on the activity of human hepatic CYP3A. , 1992, Biochemical pharmacology.

[70]  C. Hunt,et al.  Hepatic cytochrome P-4503A (CYP3A) activity in the elderly , 1992, Mechanisms of Ageing and Development.

[71]  C. Hunt,et al.  Effect of normal aging on the activity of human hepatic cytochrome P450IIE1. , 1990, Biochemical pharmacology.

[72]  L. Bruckner-Tuderman,et al.  Delayed type hypersensitivity to fusidic acid in patients with chronic dermatitis , 1990, The Lancet.

[73]  S. Norrby.  Antibiotic therapy in aging patients. , 1987, Bulletin of the New York Academy of Medicine.

[74]  H. Lassman,et al.  Roxithromycin: a pharmacokinetic review of a macrolide. , 1987, The Journal of antimicrobial chemotherapy.

[75]  J. Ouslander.  Drug therapy in the elderly. , 1981, Annals of internal medicine.

[76]  D. Evered.  Endocrine and metabolic diseases. Treatment of thyroid disease: I. , 1976, British medical journal.

[77]  T. Horio.  Chlorpromazine photoallergy. Coexistence of immediate and delayed type. , 1975, Archives of dermatology.

[78]  T. Watanabe,et al.  [Absorption, distribution and excretion of 14C-josamycin and 14C-josamycin propionate in rats (author's transl)]. , 1975, The Japanese journal of antibiotics.

[79]  H. Gavras,et al.  Biliary excretion of 35 S-labelled propylthiouracil, methimazole and carbimazole in untreated and pentobarbitone pretreated rats. , 1972, Biochemical pharmacology.